2026· EPJ Web of Conferences· Vol 381, pp. 00007· 0 citations· 6 references
TL;DR
This work evaluates five pre-trained CNN architectures- ResNet50, EfficientNetB0, DenseNet121, InceptionV3, and MobileNetV2- on the SIPaKMeD cervical cell dataset, within a unique, controlled experimental framework, providing a repeatable starting point for subsequent optimization work.
Abstract
Early detection of cervical cancer remains a major public health challenge, particularly in countries where screening programs are underfunded or inaccessible. Despite the growing number of studies applying convolutional neural networks (CNNs) to analyse cytological images, most use heterogeneous experimental protocols, making it difficult to draw meaningful comparisons across architectures. We bridge this gap by evaluating five pre-trained CNN architectures- ResNet50, EfficientNetB0, DenseNet121, InceptionV3, and MobileNetV2- on the SIPaKMeD cervical cell dataset, within a unique, controlled experimental framework. Each model is run with the same preprocessing pipeline, the same transfer learning policy (80%-layer freezing), and the same training hyperparameters. We evaluated each model in two contexts: a five-class cellular classification task and a clinically driven three-class clustering task, using accuracy, macro-precision, macro-recall, and macro-F1-score. Our best result- where DenseNet121 achieved 96.93% ± 0.38 in the five-class framework and 97.47% ± 0.47 in the three-class framework- outperforms all results obtained using a single architecture previously published on this dataset under similar conditions. The framework we describe provides a repeatable starting point for subsequent optimization work.
Cervical cancer remains one of the leading causes of mortality among women worldwide, and early, accurate detection is crucial for effective treatment. Conventional cytological screening suffers from inter-observer variability and limited accuracy, prompting increased adoption of artificial intelligence, Machine Learni...
V. Sushma, J. Gorabal, Sagargouda Patil· Engineering, Technology &...· 0 citations
Results indicate the potential of the proposed CAD framework to support radiologists as a second-reader tool in lung cancer screening, pending further external validation, and are competitive with, and in several respects exceed, recently reported approaches on the same dataset.
Anand G. Sharma, N. Kandoi, Priyanka V. Deshmukh· Egyptian Journal of Bronchol...· 0 citations
Introduction Cervical cancer screening relies heavily on manual cytopathological evaluation, which is subjective and prone to inter-observer variability. While deep learning offers automated alternatives, existing models often struggle to capture both global cellular context and fine-grained biological nuances. To addr...
M. Rahman, Md. Tofael Ahmed Bhuiyan, Md Fokrul Islam Khan et al.· Frontiers in Oncology· 0 citations
Background Tissue microarray (TMA) technology is pivotal in cancer research, enabling simultaneous analysis of multiple samples on a single slide. Manual analysis of TMA images remains time-consuming and subjective. This study aimed to develop a robust deep learning model to automate TMA image analysis, enhance accurac...
Kuo-Wang Tsai, Bach-Tung Pham, Ching-Feng Cheng et al.· Journal of Cancer· 0 citations
STLC-Net (Skin Transfer Learning Classification Network) is introduced, a robust, zero-data-leakage framework for automated seven-class skin lesion classification using the benchmark HAM10000 dataset and integrated into an interactive web deployment for real-time, interpretable clinical decision support.
When it comes to cancers affecting women, breast cancer is still at the top of the list and a huge problem for public health. The key to better patient outcomes and lower mortality rates is early and precise diagnosis. In order to overcome these obstacles, this research presents a hybrid framework that uses deep learni...
D. Baswaraj, Y. Sucharitha, S. Nithyapriya et al.· 2026 6th International Confe...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.